Residency · Residency · Vascular Surgery
Lymphedema: Diagnosis and Management
Introduction
Lymphedema is a chronic condition characterized by impaired lymphatic drainage, which leads to the accumulation of protein-rich interstitial fluid and progressive swelling of the affected tissues. Although it is not primarily a vascular disease, lymphedema often presents to vascular surgeons and shares significant clinical overlap with venous disorders. Accurate diagnosis and early intervention are essential to prevent irreversible tissue changes and to improve patients' quality of life.
Classification
Primary Lymphedema
Primary lymphedema arises from congenital malformations or dysfunctions of the lymphatic system. The most common form is lymphedema praecox, also known as Meige disease, which typically manifests around puberty and shows a female predominance. Lymphedema congenita, or Milroy disease, presents at birth and is linked to an autosomal dominant mutation in the VEGFR-3 gene. The least common form, lymphedema tarda, develops after the age of 35.
Secondary Lymphedema
Secondary lymphedema is the most prevalent form worldwide and results from acquired damage to the lymphatic system. The leading cause globally is filariasis, caused by the parasite Wuchereria bancrofti, which is endemic in tropical regions. Cancer treatments such as lymph node dissection and radiation therapy, particularly for breast cancer, melanoma, and gynecologic malignancies, are common causes. Surgical disruption during procedures like groin dissection in vascular surgery or saphenous vein harvesting can also lead to secondary lymphedema. Additionally, chronic venous insufficiency may cause secondary lymphatic overload, and recurrent cellulitis can result in lymphatic scarring. Obesity is another recognized risk factor for secondary lymphedema.
Pathophysiology
Lymphatic obstruction or insufficiency leads to the accumulation of protein-rich fluid in the interstitial space. This chronic protein accumulation stimulates fibroblast proliferation, collagen deposition, and hypertrophy of adipose tissue. Over time, progressive fibrosis renders the edema resistant to elevation and compression. The impaired immune surveillance within the affected tissues predisposes patients to recurrent cellulitis and lymphangitis. In end-stage lymphedema, also known as elephantiasis, there is massive tissue fibrosis accompanied by papillomatosis and characteristic skin changes.
Diagnosis
Clinical Assessment
The Stemmer sign is a key clinical test for lymphedema; it is positive when one is unable to pinch a fold of skin at the base of the second toe, distinguishing lymphedema from lipedema, where the sign is negative. Bilateral limb circumference measurements at standardized levels help quantify swelling. In advanced stages, the edema becomes non-pitting, although pitting may be present early in the disease. Skin changes include thickening, a peau d'orange (orange peel) appearance, hyperkeratosis, and papillomatosis. The distribution of swelling in lymphedema typically involves the dorsum of the foot and toes, unlike venous edema, which usually spares the toes.
Imaging
Lymphoscintigraphy is the gold standard for confirming lymphatic dysfunction. This technique involves subdermal injection of a radiolabeled colloid, which is then tracked to regional lymph nodes. Delayed or absent uptake in these nodes, dermal backflow patterns, and asymmetric transport confirm the diagnosis. Indocyanine green (ICG) lymphography uses near-infrared fluorescence to image superficial lymphatic channels and is particularly useful for surgical planning. MRI lymphangiography provides detailed anatomic assessment of lymphatic channels and tissue composition. Duplex ultrasound is employed to exclude venous disease as a contributing factor.
Staging (International Society of Lymphology)
The International Society of Lymphology classifies lymphedema into five stages. Stage 0, or subclinical lymphedema, involves lymphatic damage without visible edema and may be detected only by lymphoscintigraphy. Stage I is characterized by pitting edema that resolves with limb elevation and no fibrosis. Stage II is divided into early and late phases: early Stage II features pitting edema that does not fully resolve with elevation, while late Stage II presents with non-pitting edema and tissue fibrosis. Stage III, known as elephantiasis, involves massive edema with skin changes such as papillomatosis and fibrosis.
| ISL Stage | Name | Edema Character | Response to Elevation | Tissue Changes |
|---|---|---|---|---|
| 0 | Subclinical | No visible edema | N/A | Lymphatic damage detectable on lymphoscintigraphy |
| I | Spontaneously reversible | Pitting | Resolves | No fibrosis |
| II (early) | Spontaneously irreversible | Pitting | Does not fully resolve | Early fibrosis |
| II (late) | Spontaneously irreversible | Non-pitting | Does not resolve | Tissue fibrosis |
| III | Elephantiasis | Massive, non-pitting | Does not resolve | Papillomatosis, severe fibrosis, skin changes |
Conservative Management
Complete Decongestive Therapy (CDT)
Complete decongestive therapy is the cornerstone of conservative management and consists of two phases. Phase I, the intensive reduction phase, is performed by certified lymphedema therapists and includes manual lymphatic drainage (MLD), a gentle massage technique that redirects lymph to functional drainage pathways. Multi-layer compression bandaging with short-stretch bandages is applied daily to maintain volume reduction. Skin care and hygiene are emphasized to prevent infection, and therapeutic exercise is performed while wearing compression. Phase II, the maintenance phase, involves the use of compression garments with pressures of 30-40 mmHg or higher, self-administered MLD, continued skin care, and exercise. In compliant patients, CDT can achieve volume reductions of 40% to 60%.
Compression Therapy
Long-term management relies on custom-fitted compression garments, typically Class II or III. Pneumatic compression devices may be used as adjuncts to manual therapy. For advanced disease, nighttime compression with foam-padded garments is often employed.
Pharmacologic and Adjunctive Therapy
Diuretics are ineffective in treating lymphedema and may worsen the protein concentration in tissues, so they should be avoided. Antibiotics are used to treat acute cellulitis, usually targeting streptococci, with penicillin or amoxicillin being common choices. For patients experiencing recurrent cellulitis (more than two episodes per year), prophylactic antibiotics such as penicillin V at 250 mg twice daily are recommended. Weight management is important in obese patients to reduce lymphedema severity.
Surgical Management
Physiologic (Reconstructive) Procedures
Physiologic procedures aim to restore lymphatic function. Lymphovenous anastomosis (LVA) involves microsurgical connections between lymphatic channels and subdermal venules and is most effective in early-stage disease (ISL stages I-II). Vascularized lymph node transfer (VLNT) entails transplanting an autologous lymph node flap to the affected extremity to promote lymphangiogenesis. Indocyanine green lymphography is essential for preoperative planning and for identifying functional lymphatic channels.
Reductive (Debulking) Procedures
Reductive procedures address the tissue overgrowth component of lymphedema but do not restore lymphatic function. Suction-assisted protein lipectomy (SAPL) uses liposuction to remove fibrotic and adipose tissue in advanced lymphedema; patients require lifelong use of compression garments postoperatively. The Charles procedure involves radical excision of skin and subcutaneous tissue followed by skin grafting and is reserved for severe elephantiasis.
Complications
The most common complication of lymphedema is recurrent cellulitis and lymphangitis, which can accelerate lymphatic damage. A rare but aggressive malignancy called lymphangiosarcoma, or Stewart-Treves syndrome, may arise in chronic lymphedema, typically presenting as purple nodules after 10 or more years of disease. Lymphedema also causes functional impairment and reduces quality of life. The psychological impact includes body image disturbance, depression, and social isolation.
Key Clinical Pearls
A positive Stemmer sign is virtually diagnostic of lymphedema and helps distinguish it from lipedema and venous edema. Complete decongestive therapy remains the cornerstone of management, and early referral to a certified therapist is crucial. Diuretics are ineffective and should be avoided in lymphedema treatment. Lymphovenous anastomosis offers the best outcomes when performed in early-stage disease before fibrosis develops. Any new nodule or skin change in a chronically lymphedematous limb should raise suspicion for lymphangiosarcoma and warrants prompt biopsy.
References
- Defined, Defined, et al. "The diagnosis and treatment of peripheral lymphedema: 2020 consensus document of the ISL." Lymphology. 2020;53(1):3-19.
- Defined, Defined, et al. "Lymphovenous anastomosis for lower extremity lymphedema: a systematic review." J Vasc Surg Venous Lymphat Disord. 2019;7(4):553-562.
- Defined, Defined, et al. "Complete decongestive therapy for treatment of lymphedema." Semin Intervent Radiol. 2008;25(3):155-161.
- Defined, Defined, et al. "Lymphangiosarcoma in chronic lymphedema (Stewart-Treves syndrome): review of the literature." Lymphology. 2012;45(4):153-163.